Dr Reddys Laboratories Share Price Today - Live Blog for June 06, 2025

With a -0.11% decrease, Dr Reddys Laboratories Ltd's share price is now ₹1,320.50. Investors should examine the factors driving this decline. The stock's PE ratio is 18.4800, whereas the industry PE ratio stands at 33.6755.

In a noteworthy development, Dr Reddys Laboratories Ltd witnessed a remarkable 0.05% increase in its share price. This surge in value has sparked heightened investor interest, with the stock currently trading at ₹1,321.65 per share. The stock has an ROE of 16.8559% and debt to equity ratio of 0.1394.

The stock price of Dr Reddys Laboratories Ltd enjoyed a significant 0.00% boost, with the current market value at ₹1,320.10 per share. This surge has not gone unnoticed by investors.

Dr Reddys Laboratories Ltd's share price has dropped by -0.04%, a development that warrants careful analysis. Presently trading at ₹1,319.50, investors are assessing whether this presents an opportunity or a risk.

The share price of Dr Reddys Laboratories Ltd experienced a -0.06% slump and is currently trading at ₹1,319.15. While the stock maintains a PE ratio of 18.4800, the industry PE is 33.6755, raising questions about valuation.

After a significant 0.07% gain, Dr Reddys Laboratories Ltd's shares are now valued at ₹1,319.95 in the current market. This upward movement is attracting attention from both retail and institutional investors.

With a -0.03% decrease, Dr Reddys Laboratories Ltd's share price is now ₹1,319.00. Investors should examine the factors driving this decline. The stock's PE ratio is 18.4800, whereas the industry PE ratio stands at 33.6755.

The share price of Dr Reddys Laboratories Ltd has plummeted by -0.01%, signalling a challenging period. Currently trading at ₹1,319.50, this stock has caught the eye of bargain hunters, who may be considering their entry points.

Dr Reddys Laboratories Ltd share price has declined by -0.18%, and it's currently trading at ₹1,318.80. The stock maintains a PE of 18.4800, while the industry PE is 33.6755, prompting discussions about its valuation.

The stock of Dr Reddys Laboratories Ltd is making significant strides, boasting a 0.03% increase and currently trading at ₹1,320.55 per share. This upward trajectory is turning heads in the market.

Dr Reddys Laboratories Ltd experienced a substantial 0.04% boost in its share price and has garnered significant attention from the market. It's now trading at ₹1,313.35, making it an appealing option for investors.

Increased investor interest has propelled Dr Reddys Laboratories Ltd's stock to a significant 0.04% gain, with the share price now at ₹1,313.35. Notably, the stock's PE ratio stands at 18.4800, and its Return on Equity (ROE) is 16.8559%.

Increased investor interest has propelled Dr Reddys Laboratories Ltd's stock to a significant 0.04% gain, with the share price now at ₹1,313.35. Notably, the stock's PE ratio stands at 18.4800, and its Return on Equity (ROE) is 16.8559%.

Increased investor interest has propelled Dr Reddys Laboratories Ltd's stock to a significant 0.07% gain, with the share price now at ₹1,314.00. Notably, the stock's PE ratio stands at 18.4800, and its Return on Equity (ROE) is 16.8559%.

Dr Reddys Laboratories Ltd's share price has dropped by -0.17%, a development that warrants careful analysis. Presently trading at ₹1,312.25, investors are assessing whether this presents an opportunity or a risk.

The share price of Dr Reddys Laboratories Ltd experienced an uptrend, surging by 0.24% recently. As of now, this stock is actively trading at a current market price of ₹1,314.55 per share, attracting attention from investors.

Dr Reddys Laboratories Ltd witnessed a -0.01% decrease in its share price, and it is currently trading at ₹1,312.50. This decline has prompted discussions among investors regarding the stock's performance and outlook. The stock has a PE ratio of 18.4800, an ROE of 16.8559% and a debt to equity ratio of 0.1394.

In recent times, Dr Reddys Laboratories Ltd witnessed a decline of -0.06% in its share price, and it currently trades at ₹1,311.50 per share. The stock has an ROE of 16.8559% and debt to equity ratio of 0.1394.

With a -0.01% decrease, Dr Reddys Laboratories Ltd's share price is currently at ₹1,311.85. This development raises questions about the factors behind the decline. The stock's PE ratio is 18.4800, while the industry PE is 33.6755.

Dr Reddys Laboratories Ltd's stock has surged by 0.29%, and it is currently trading at ₹1,312.85. Additionally, the stock maintains a PE ratio of 18.4800, while the industry PE is 33.6755.

Dr Reddys Laboratories Ltd's stock has surged by 0.30%, and it is currently trading at ₹1,310.00. Additionally, the stock maintains a PE ratio of 18.4800, while the industry PE is 33.6755.

The share price of Dr Reddys Laboratories Ltd plunged by -0.00%, leaving investors concerned. At this moment, the stock can be acquired at ₹1,306.00, but investors are assessing whether this is a temporary dip or a long-term trend.

Dr Reddys Laboratories Ltd's share price remained the same, currently trading at ₹1,305.50. This unchanging trend might prompt investors to reevaluate their investment thesis and consider factors influencing the stock's stability.

In a noteworthy development, Dr Reddys Laboratories Ltd witnessed a remarkable 0.34% increase in its share price. This surge in value has sparked heightened investor interest, with the stock currently trading at ₹1,304.90 per share. The stock has an ROE of 16.8559% and debt to equity ratio of 0.1394.

Dr Reddys Laboratories Ltd observed a remarkable 0.34% surge in its share price and is presently trading at ₹1,304.90. The increased investor interest is driving this surge.

The stock of Dr Reddys Laboratories Ltd suffered a -0.47% decline, and it currently trades at ₹1,299.75 per share. Investors are closely monitoring this situation, looking for potential signs of recovery.

The stock of Dr Reddys Laboratories Ltd is making significant strides, boasting a 1.08% increase and currently trading at ₹1,306.10 per share. This upward trajectory is turning heads in the market.